• Explore /
  • Poster
  • / Quantitative proteomic analysis of TUBB3 to identify gastric cancer patients who may benefit from docetaxel: A reevaluation of the ITACA-S trial.

Quantitative proteomic analysis of TUBB3 to identify gastric cancer patients who may benefit from docetaxel: A reevaluation of the ITACA-S trial.

Abstract Poster

Authors

Fabiola Cecchi

Fabiola Cecchi

NantOmics, LLC., Rockville, MD

Fabiola Cecchi , Daniel V.T. Catenacci , Yuan Tian , Rosalba Miceli , Filippo Pietrantonio , Alessandro Pellegrinelli , Antonia Martinetti , Maria Di Bartolomeo , Todd A. Hembrough

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Translational Research

Clinical Trial Registration Number

NCT01989858

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 59)

DOI

10.1200/JCO.2017.35.4_suppl.59

Abstract #

59

Poster Bd #

F15

Abstract Disclosures

Similar Posters

First Author: Jun-Eul Hwang

First Author: Hongjae Chon

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.

Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.

First Author: Ali Fawaz

First Author: Toshiharu Hirose